preanalytical factors comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-12. Numbers and descriptions here follow the published literature rather than marketing material.
For solid glutathione reagents, storage at low temperature and protection from moisture and light are typical precautions. Aqueous solutions can oxidize over time, and pH affects stability; alkaline conditions generally promote thiol oxidation. Some protocols prepare fresh solutions, while others use antioxidants or chelators to limit metal-catalyzed oxidation. Purity and counterion content can vary among commercial preparations, affecting concentration calculations. Certificates of analysis and validated assays help verify identity and purity.
Measuring glutathione in biological samples requires attention to oxidation, because GSH can convert to GSSG after sample collection. Blood and plasma samples are often treated with acid or alkylating agents to preserve the reduced form. Without stabilization, apparent GSH concentrations can fall while GSSG rises. Differences in sample type, handling delay, and deproteinization method can produce results that are not comparable across studies. Reporting preanalytical details is therefore important for interpreting findings.
Glutathione supports detoxification by conjugating reactive electrophiles through glutathione S-transferases. The resulting conjugates are processed and exported, often after further metabolism. It also stores cysteine, transports amino acids across membranes through the gamma-glutamyl cycle, and assists in the maturation of iron-sulfur clusters and some prostaglandins. In plants, animals, and many microbes, the molecule appears in similar roles, but concentrations vary enormously between tissues. Liver, kidney, and red blood cells tend to contain high amounts, while blood plasma contains much less.
Glutathione is a small tripeptide built from glutamate, cysteine, and glycine. The peptide bond between glutamate and cysteine uses the gamma-carboxyl group, a linkage that resists ordinary peptidases. Cells make it in two ATP-dependent steps: gamma-glutamylcysteine synthetase joins glutamate and cysteine, then glutathione synthetase adds glycine. The pathway is feedback-inhibited by glutathione itself, so intracellular levels tend to stay within a narrow range. Because cysteine is often limiting, sulfur amino acid supply influences how much glutathione a cell can produce.
In its reduced form, glutathione carries a sulfhydryl group that can donate electrons. This property lets it act as a major cellular antioxidant and redox buffer. Glutathione peroxidase uses it to reduce hydrogen peroxide and lipid peroxides, while glutathione reductase regenerates the reduced form using NADPH. The ratio of reduced glutathione to glutathione disulfide is widely used as an indicator of oxidative stress, though the ratio changes with compartment, cell type, and sample handling. Oxidized glutathione can also form mixed disulfides with proteins, affecting their activity.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | LC-MS/MS, HPLC, or enzymatic recycling | Choice depends on whether total, reduced, or oxidized glutathione is measured. |
| Sample stabilization | Acidification or thiol alkylation | Helps limit conversion of GSH to GSSG after collection. |
| Solution stability | Limited at room temperature | Oxidation and pH-dependent degradation can occur. |
| Storage of solid | -20 °C, desiccated, protected from light | Common for research reagents; follow supplier instructions. |
| Common interference | Other thiols and metal ions | Can affect separation or enzymatic detection. |
Quality control for glutathione materials checks identity, assay, purity, water content, and disulfide content. Commercial products vary from research-grade powder to dietary supplements, and labels may not distinguish reduced from oxidized forms. In the United States, oral glutathione is commonly sold as a dietary supplement rather than an approved drug, while injectable forms fall under different rules and may require a prescription. Regulatory status differs by country. Analytical certificates, when available, help verify what a material contains, but independent testing remains important for interpretation.
Laboratory measurement of glutathione typically starts with rapid acid extraction to prevent oxidation and enzymatic degradation. Common methods include enzymatic recycling assays, high-performance liquid chromatography, and liquid chromatography coupled with mass spectrometry. The recycling assay uses glutathione reductase and a thiol-reactive colorimetric or fluorescent reagent, measuring total glutathione after converting disulfide forms. Chromatographic methods can separate reduced and oxidized forms, which helps when the redox ratio is the target. Choice of method affects sensitivity, specificity, and the amount of sample needed.
Samples for glutathione analysis require careful handling because the compound oxidizes readily and can be consumed by enzymes after collection. Blood is often treated with acid or thiol-blocking agents soon after draw, and plasma should be separated quickly from red blood cells. Tissues are usually snap-frozen or extracted immediately. Aqueous solutions of glutathione are less stable than dry powder and degrade faster at neutral or alkaline pH, in light, or with dissolved oxygen. Repeated freeze-thaw cycles also reduce reliability.
Synthesis occurs in two ATP-dependent steps: glutamate-cysteine ligase joins glutamate and cysteine to form gamma-glutamylcysteine, and glutathione synthetase adds glycine to complete the tripeptide. The pathway is feedback-inhibited by GSH and limited by cysteine availability, so cysteine supply often constrains production. Once formed, GSH participates in redox buffering, xenobiotic conjugation, and protein glutathionylation. Glutathione peroxidase uses GSH to reduce hydrogen peroxide and lipid peroxides, yielding GSSG, while glutathione reductase regenerates GSH using NADPH. Glutathione S-transferases conjugate electrophiles to GSH, supporting detoxification and excretion.
Because GSH is central to redox balance, its status is studied in aging, liver disease, neurodegenerative conditions, and metabolic disorders. Observational studies often report lower GSH or higher GSSG in affected tissues, but such associations do not establish that raising glutathione changes disease outcomes. Oral glutathione is digested into amino acids, and whether intact absorption occurs remains debated; precursors such as N-acetylcysteine and cysteine donors are also investigated. Regulatory agencies generally treat glutathione as a dietary supplement, not an approved drug, and clinical claims require evidence from controlled trials.
Glutathione is a small tripeptide composed of glutamate, cysteine, and glycine, with the unusual gamma-glutamyl linkage between glutamate and cysteine. Its cysteine thiol group makes it a major non-enzymatic antioxidant in cells. The reduced form, GSH, predominates in most intracellular compartments, while the oxidized disulfide form, GSSG, is produced when GSH reduces reactive oxygen species. Intracellular concentrations often reach millimolar levels, whereas plasma concentrations are much lower, typically in the low micromolar range. This gradient reflects active synthesis, transport, and consumption rather than passive distribution.
Quantifying glutathione requires distinguishing GSH from GSSG and preventing oxidation during sample preparation. Common approaches include the enzymatic recycling assay, often called the Tietze method, which measures total glutathione after converting GSSG to GSH. HPLC with ultraviolet or fluorescence detection and LC-MS/MS can separate and quantify both forms, sometimes after derivatization of the thiol group. Blood, plasma, and tissue samples differ in matrix and baseline concentrations, so method validation must account for recovery, linearity, and interference. No single assay is universally standard.
Glutathione is most stable as a dry powder stored cool and dry, but its thiol group is readily oxidized in solution. Aqueous preparations at neutral or alkaline pH lose GSH faster because the thiolate form reacts with dissolved oxygen and metal ions. Acidic conditions, chelating agents, and oxygen exclusion can slow oxidation, while repeated freeze-thaw cycles promote degradation. Light exposure and trace metals also contribute to loss. Laboratories typically validate stability for their own matrices because degradation rates depend on pH, temperature, concentration, and container materials.
=== Murder conviction === Cochran was later convicted of first-degree murder in state court for poisoning her husband, Michael Brandon Cochran, with insulin. Prosecutors argued that Michael had grown suspicious of their business dealings and planned to investigate further. On February 5, 2019, Cochran canceled Michael’s flight to Virginia, where he intended to investigate their business dealings, and injected him with insulin. Despite his deteriorating condition, Cochran refused to take him to the hospital, telling friends he would “sleep it off.” Michael died on February 11, 2019. During the trial, forensic experts confirmed that Michael’s death was caused by nonprescribed insulin. Prosecutors argued that Cochran killed her husband to prevent him from uncovering her fraudulent activities. The jury deliberated for less than two hours before delivering a guilty verdict. In January 2025, Cochran was sentenced to life imprisonment without parole, with the jury recommending no mercy. After announcing in November 2023 that he would not run for re-election at the end of 2024, Judge H.L. Kirkpatrick, stated that he would preside over the Natalie Cochran trial by special appointment.
== Epidemiology == Sjögren's disease (SjD) is the third-most common rheumatic autoimmune disorder, behind rheumatoid arthritis and systemic lupus erythematosus. There are no geographical differences in the rates of Sjögren's. Sjögren's disease has been reported in all areas of the world, although regional rates have not been well studied. Depending on the criteria to determine prevalence, studies estimate the prevalence of Sjögren's at between 500,000 and 2 million people in the United States. Broader studies of Sjögren's prevalence vary widely, with some reports suggesting a prevalence of up to 3% of the population. A few studies have reported that the incidence of the syndrome ranges between three and six per 100,000 per year. Between 0.2 and 1.2% of the population is affected, with half having the primary form and half the secondary form. It is around 10 times more common in women than in men. Though the disease commonly begins in middle age, people of any age can be affected. Nine out of 10 Sjögren's patients are women. In addition to prevalence in women, having a first-degree relative with an autoimmune disease and previous pregnancies have been identified as epidemiological risk factors. Despite the lower risk for men, primary Sjögren's in men tends to represent a more severe form of the disease. The role of race and ethnicity in the prevalence of the disease is unknown. Although Sjögren's disease occurs in all age groups, the average age of onset is between 40 and 60. As many as half of all cases may be left undiagnosed or unreported.
== 16α-Hydroxylation == Through the action of CYP1A1, CYP1A2, CYP2C8, and the CYP3A isoforms, 16α-hydroxyestradiol (16α-OHE2), also known as estriol, is produced in abundance during pregnancy. 16α-OHE2 can be dehydrogenated to 16α-hydroxyestrone (16α-OHE1), a metabolite that has been shown to bind covalently to the estrogen receptor via Schiff base formation. This covalent linkage occurs between the steroid carbonyl and the ε-amino group of lysine. In theory, 16α-OHE1 could also bind DNA, although this has not been observed. 16α-OHE2 is a potent ER agonist, capable of levels of cellular proliferation stimulation that near those obtained with E2. Though studies in hamster kidney tumor models showed weak carcinogenicity, the carcinogenic potential of 16α-OHE2 in humans remains unknown.
== Proteins which contain the ICK motif == Agouti related peptide Agouti signalling peptide Albumin I Covalitoxin-II DkTx Grammotoxin GsMTx-4 Guangxitoxin Hainantoxin Hanatoxin Heteroscodratoxin-1 Huwentoxin Maurocalcine Theraphosa leblondi toxin δ-Palutoxin Phrixotoxin Psalmotoxin Robustoxin Stromatoxin Tachystatin Vanillotoxin Vejocalcin
=== Extraction for treatment === Extracted growth hormone was used since the late 1950s until the late 1980s when its use was replaced by recombinant GH. In the late 1950s, Maurice Raben purified enough GH from human pituitary glands to successfully treat a GH-deficient boy. A few endocrinologists began to help parents of severely GH-deficient children to make arrangements with local pathologists to collect human pituitary glands after removal at autopsy. Parents would then contract with a biochemist to purify enough growth hormone to treat their child. Few families could manage such a complicated undertaking. In 1960, the National Pituitary Agency was formed as a branch of the U.S. National Institutes of Health. The purpose of this agency was to supervise the collection of human pituitary glands when autopsies were performed, arrange for large-scale extraction and purification of GH, and distribute it to a limited number of pediatric endocrinologists for treating GH-deficient children under research protocols. Canada, UK, Australia, New Zealand, France, Israel, and other countries establish similar government-sponsored agencies to collect pituitaries, purify GH, and distribute it for treatment of severely GH-deficient children. Supplies of this "cadaver growth hormone" were limited, and only the most severely deficient children were treated. From 1963 to 1985 about 7,700 children in the U.S. and 27,000 children worldwide were given GH extracted from human pituitary glands to treat severe GH deficiency.
Sources: en.wikipedia.org
=== 1947–1969: Unions and foundations === The Nederlandse Radio Unie (Netherlands Radio Union; NRU) was established in 1947. After several failed attempts to create a public broadcasting system and link up with a national station, the NRU was created as a union of broadcasting associations that provided operational support. The associations were responsible for their output, but studios, orchestras, and outside broadcast facilities were managed by the NRU. Weekly radio plays were also the domain of the NRU and would run until 1986. The NRU became the Dutch founding member of the European Broadcasting Union in 1950. Meanwhile, the Nederlandse Televisie Stichting (Netherlands Television Foundation; NTS) was created in 1951, two years after public television returned to the airwaves. The NTS served as a similar organisation to the NRU, in that broadcast and transmission facilities were supplied to member associations for making programmes. It was not until 1956 that the NTS itself produced its first programme, a news bulletin called the NTS Journaal. This was followed by a sports round-up, Sport in Beeld (Sports Illustrated) in 1959, and 1967 Langs de Lijn (Along the Line), a joint production of several broadcasting associations. On 15 October 1967, Willem Leonard Oltmans interviewed the de Mohrenschildts for the NTS, which resulted in a 40-minute film that was the only full-length filmed interview of George de Mohrenschildt. However, the film, which was kept at Hilversum, disappeared in 1975.
Myxomas Atrial myxoma Odontogenic myxoma Cutaneous myxoma Intramuscular myxoma Myxoid hamartoma Aggressive angiomyxoma Myxoid leiomyoma Chondromyxoid fibroma Myxoid neurofibroma Nerve sheath myxoma (neurothekeoma) Myxolipoma Angiomyofibroblastoma Myxoid leiomyosarcoma Myxoid liposarcoma Lipoblastoma Myxofibrosarcoma Myxoid cortical adenoma Pleomorphic adenoma Undifferentiated embryonal sarcoma Plexiform angiomyxoid myofibroblastic tumor Myxoid plexiform fibrohistiocytic tumor Angiomyxolipoma (vascular myxolipoma) Parachordoma Acral myxoinflammatory fibroblastic sarcoma
=== Neuromuscular fatigue === Nerves control the contraction of muscles by determining the number, sequence, and force of muscular contraction. When a nerve experiences synaptic fatigue it becomes unable to stimulate the muscle that it innervates. Most movements require a force far below what a muscle could potentially generate, and barring pathology, neuromuscular fatigue is seldom an issue. For extremely powerful contractions that are close to the upper limit of a muscle's ability to generate force, neuromuscular fatigue can become a limiting factor in untrained individuals. In novice strength trainers, the muscle's ability to generate force is most strongly limited by nerve's ability to sustain a high-frequency signal. After an extended period of maximum contraction, the nerve's signal reduces in frequency and the force generated by the contraction diminishes. There is no sensation of pain or discomfort; instead, the muscle appears to simply "stop listening." and gradually cease to move, often lengthening. As there is insufficient stress on the muscles and tendons, there will often be no delayed onset muscle soreness following the workout. Part of the process of strength training is increasing the nerve's ability to generate sustained, high frequency signals which allow a muscle to contract with their greatest force. It is this "neural training" that causes several weeks worth of rapid gains in strength, which level off once the nerve is generating maximum contractions and the muscle reaches its physiological limit.
== History and development == A recipe for cream soda written by E. M. Sheldon and published in Michigan Farmer in 1852 called for water, cream of tartar (potassium bitartrate), Epsom salts, sugar, egg, and milk to be mixed, then heated, then mixed again once cooled with water and a quarter teaspoonful of baking soda to make an effervescent drink. It was suggested as a temperance drink preferable to those of "Uncle Bacchus" and in compliance with the recently introduced Maine law. An alternative recipe can be found combining a soda of choice as well as whipped cream. Alexander C. Howell of Vienna, New Jersey, was granted a patent for "cream soda-water" on June 27, 1865. Howell's cream soda-water was made with sodium bicarbonate, water, sugar, egg whites, wheat flour, and "any of the usual flavoring materials—such as oil of lemon, extracts of vanilla, pine-apple, to suit the taste". Before drinking, the cream soda-water was mixed with water and an acid, such as tartaric acid or citric acid. In Canada, James William Black of Berwick, Nova Scotia, was granted a U.S. patent on December 8, 1885, and a Canadian patent on July 5, 1886, for "ice-cream soda". Black's ice-cream soda, which contained whipped egg whites, sugar, lime juice, lemons, citric acid, flavoring, and bicarbonate of soda, was a concentrated syrup that could be reconstituted into an effervescent beverage by adding ordinary ice water. In the United States, Ugo H. Sodini helped to pioneer in the creation of vanilla cream soda.
=== Other antibiotics === Alternatives to fosfomycin include nitrofurantoin, pivmecillinam, and co-amoxiclav in oral treatment of urinary-tract infections associated with extended-spectrum beta-lactamase. In a separate study, CRE were treated with colistin, amikacin, and tigecycline, and emphasizes the importance of using gentamicin in patients undergoing chemotherapy or stem-cell therapy procedures. While colistin had shown promising activity against carbapenemase-producing isolates, more recent data suggest a resistance to it is already emerging and it will soon become ineffective. Using another antibiotic concomitantly with carbapenem can help prevent the development of carbapenem resistance. One specific study showed a higher rate of carbapenem resistance when using meropenem alone compared with combination therapy with moxifloxacin. In addition, several drugs were tested to gauge their effectiveness against CRE infections. In vitro studies have shown that rifampin has synergistic activity against carbapenem-resistant E. coli and K. pneumoniae. However, more data are needed to determine if rifampin is effective in a clinical setting. Several new agents are in development. The main areas where scientists are focusing is new β-lactamase inhibitors with activity against carbapenemases. Some of these include MK-7655, NXL104, and 6-alkylidenepenam sulfones. The exact way they affect the carbapenemases is unknown. Another experimental agent with activity against CRE is eravacycline.
Sources: en.wikipedia.org
Preanalytical factors such as sample type, time to processing, and stabilization method can change GSH and GSSG amounts. Analytical method and calibration also contribute to variation. Comparing absolute values across studies requires caution.
These assays typically measure total glutathione after oxidizing or reducing steps convert GSSG to GSH. A colorimetric or fluorometric signal is proportional to the recycling reaction. They generally do not report GSH and GSSG separately unless additional steps are used.
Solutions are often prepared fresh and kept cold, with protection from light and oxygen exposure. Chelating agents may reduce metal-catalyzed oxidation. Storage recommendations vary by buffer, pH, and concentration, so protocol-specific guidance should be followed.
It is a tripeptide of glutamate, cysteine, and glycine. The glutamate-cysteine bond is unusual because it forms through the gamma-carboxyl group.